Tofacitinib in Juvenile Idiopathic Arthritis

Consorci Sanitari de l'Alt Penedès i Garraf

Status: Not yet enrolling

Conditions: Juvenile Idiopathic Arthritis (JIA)

Treatments: Drug: Tofacitinib

Study type: Observational

Funder types: Other

Identifiers

NCT07211932

CSAPG-78

Details and patient eligibility

About

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Enrollment: 58 estimated patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.

Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.

Age under 18 years at the time of the treatment indication with tofacitinib.

Exclusion criteria

Participants diagnosed with any of the following conditions:

Reactive arthritis

Arthritis associated with inflammatory bowel disease

Arthritis associated with another autoimmune disease

Trial design

58 participants in 1 patient group

Tofacitinib

Description:

Patients affected by JIA and treated with tofacitinib

Treatment:

Drug: Tofacitinib